BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim data from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for the treatment of hypertension.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical and corporate update. “We remain on track to reop

Reliv International, Inc. (NASDAQ:RELV), a marketer of nutritional supplements that promote optimal health, today reported its financial results for the third quarter of 2020.

NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, today announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019): Consolidated Net Revenue of $64.2 million, up 26% year-over-year Life Science segment delivers revenue of $34.4 million, up 97% year-over-year Diagnostics segment revenues decreased 11% year-over-year to $29.8 million, a stronger

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today is pleased to announce the appointment of Amir Boloor , President of Caspian Equity Partners, Inc., as Chair of the Company’s Board of Directors. Mr. Boloor, an independent directo

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended September 30, 2020 and provided a business update.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the third quarter ended September 30, 2020, and provided corporate highlights.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 2:00 p.m. Eastern Time. The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event. About Global Blo

--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization-- --The serum pharmacokinetics (PK) of NGM621 were linear and dose-proportional-- --NGM621 ocular PK/pharmacodynamics (PD) modeling supports potential for up to every eight-week dosing regimen-- --Enrollment of the CATALINA Phase 2 study of NGM621